August 2025 in “Ophthalmic Plastic and Reconstructive Surgery” This case report describes a 4-year-old girl with neurofibromatosis type 1 and an inoperable periorbital plexiform neurofibroma treated with selumetinib. The treatment resulted in significant tumor reduction, visual improvement, and lightening of café-au-lait macules over 8 months. The tumor volume decreased by approximately 70%, with marked resolution of proptosis and restoration of extraocular motility. Visual acuity improved from 20/100 to 20/40, and intraocular pressure stabilized without surgery. Mild adverse effects included transient elevations in creatine phosphokinase levels and mild hair loss. The case suggests selumetinib as a potential first-line treatment for similar pediatric cases, with future studies needed to assess long-term efficacy and safety.
5 citations,
February 2018 in “Military medicine” A U.S. Naval fighter pilot suffered permanent vision loss in one eye due to recurrent central serous retinopathy.
87 citations,
December 2015 in “Cochrane library” No single treatment is clearly effective for central serous chorioretinopathy.
6 citations,
January 2019 in “Dermatology Research and Practice” Many survivors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Togo suffer long-term eye and skin problems.
3 citations,
November 2021 in “Frontiers in medicine” Methotrexate effectively controls eye inflammation in Japanese patients with non-infectious uveitis but requires careful monitoring for side effects.